Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests how well tafasitamab and rituximab works for the treatment of newly diagnosed follicular lymphoma. Tafasitamab is a monoclonal antibody. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving tadasitamab and rituximab may work well to treat patients with newly diagnosed follicular lymphoma.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony rozpoznaniem chłoniaka pęcherzykowego (stopnie 1, 2 lub 3A)
- •Powiększone węzły chłonne (co najmniej 3 węzły o średnicy powyżej 3 cm) lub guz powyżej 7 cm
- •Objawy ogólne takie jak gorączka, poty nocne lub utrata wagi powyżej 10% w ostatnich 6 miesięcy
- •Zmierzone ogniska choroby widoczne w badaniach obrazowych (tomografia lub PET)
- •Zdrowe liczby komórek krwi: neutrofili ≥1500, płytek ≥75000, hemoglobiny ≥8
- •Prawidłowa funkcja wątroby i nerek (bilirubina ≤2.0, enzymy wątroby w normie)
- •Sprawność fizyczna pozwalająca na leczenie (stan ogólny ≤2 w skali ECOG)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 15, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Fred Hutch/University of Washington Cancer Consortium
Seattle, United States
Trial contact
Mengyang Di, MD, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/16/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.